Keenly-watched COVID-19 vaccine 'won't be expensive', developer says
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Moderna (MRNA) Prices 17.6M Share Common Offering at $76/Sh
May 19, 2020 5:47 AM EDTModerna, Inc. (NASDAQ: MRNA) today announced the pricing of an underwritten public offering of 17,600,000 shares of common stock at a public offering price of $76.00 per share, before underwriting discounts and commissions. In addition, Moderna has granted the underwriters a 30-day option to purchase up to... More
Mizuho Securities Reiterates Buy Rating on Pfizer (PFE) After Speaking with Management
May 18, 2020 7:01 AM EDTMizuho Securities analyst Vamil Divan reiterated a Buy rating and $42.00 price target on Pfizer (NYSE: PFE) following a conference call with management. Pfizer released updated data on their Duchenne Muscular Dystrophy (DMD) candidate at ASGCT.
Divan's overall conclusion is unchanged in that the... More
